Cathrin Skrabs

2.2k total citations
40 papers, 1.1k citations indexed

About

Cathrin Skrabs is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Cathrin Skrabs has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 26 papers in Genetics and 10 papers in Oncology. Recurrent topics in Cathrin Skrabs's work include Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Viral-associated cancers and disorders (6 papers). Cathrin Skrabs is often cited by papers focused on Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Viral-associated cancers and disorders (6 papers). Cathrin Skrabs collaborates with scholars based in Austria, Germany and United Kingdom. Cathrin Skrabs's co-authors include Markus Raderer, Ulrich Jaeger, Alexander Gaiger, Andreas Chott, Klaus Lechner, Ulrich Jäger, Ulrich Jäger, Alexander W. Hauswirth, Ingrid Simonitsch‐Klupp and Leonhard Müllauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Cathrin Skrabs

39 papers receiving 1.1k citations

Peers

Cathrin Skrabs

PFM

ONCOL

GENET

RNMI

HEMAT

Igor Aurer Croatia

Masahiro Yokoyama Japan

Biljana Mihaljević Serbia

Mars B. van ’t Veer Netherlands

Gregory Bociek United States

J. M. Vose United States

Maurizio Rupolo Italy

Carin Backlin Sweden

Manuel Gotti Italy

Celeste Bello United States

Igor Aurer Croatia

Cathrin Skrabs

531 ×0.8

PFM

449 ×1.2

ONCOL

223 ×0.7

GENET

100 ×0.5

RNMI

170 ×1.0

HEMAT

Citations per year, relative to Cathrin Skrabs Cathrin Skrabs (= 1×) peers Igor Aurer

Countries citing papers authored by Cathrin Skrabs

Since Specialization

Citations

This map shows the geographic impact of Cathrin Skrabs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathrin Skrabs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathrin Skrabs more than expected).

Fields of papers citing papers by Cathrin Skrabs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathrin Skrabs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathrin Skrabs. The network helps show where Cathrin Skrabs may publish in the future.

Co-authorship network of co-authors of Cathrin Skrabs

This figure shows the co-authorship network connecting the top 25 collaborators of Cathrin Skrabs. A scholar is included among the top collaborators of Cathrin Skrabs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathrin Skrabs. Cathrin Skrabs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wohlfarth, Philipp, Cathrin Skrabs, Winfried F. Pickl, et al.. (2024). Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 23(1). 262–266. 6 indexed citations

Porpaczy, Edit, Philipp Wohlfarth, Oliver Königsbrügge, et al.. (2021). Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers. 13(22). 5592–5592. 17 indexed citations

Porpaczy, Edit, et al.. (2018). Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib. British Journal of Haematology. 181(4). 431–431. 1 indexed citations

Mayerhoefer, Marius E., Markus Raderer, Ulrich Jaeger, et al.. (2018). Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. European Journal of Nuclear Medicine and Molecular Imaging. 45(6). 931–940. 18 indexed citations

Mayerhoefer, Marius E., Georgios Karanikas, Kurt Kletter, et al.. (2015). Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients. Clinical Cancer Research. 21(11). 2506–2513. 66 indexed citations

Schiefer, Ana‐Iris, Christoph Kornauth, Ingrid Simonitsch‐Klupp, et al.. (2015). Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. Medicine. 94(52). e2388–e2388. 19 indexed citations

Mayerhoefer, Marius E., Georgios Karanikas, Kurt Kletter, et al.. (2014). Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. Clinical Cancer Research. 20(11). 2984–2993. 81 indexed citations

Gebhart, Johanna, Klaus Lechner, Cathrin Skrabs, et al.. (2014). Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. Thrombosis Research. 134(5). 980–984. 13 indexed citations

Fiegl, Michael, Reinhard Stauder, Michael Steurer, et al.. (2013). Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of Hematology. 93(2). 267–277. 12 indexed citations

10.

Vanura, Katrina, Andreas Gleiß, Trang Le, et al.. (2011). Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis. Annals of Hematology. 90(8). 947–954. 4 indexed citations

11.

Gruber, Michaela, Edit Porpaczy, Cathrin Skrabs, et al.. (2011). Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Annals of Hematology. 90(10). 1131–1136. 10 indexed citations

12.

Heintel, Daniel, Cathrin Skrabs, Alexander W. Hauswirth, et al.. (2009). Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Annals of Hematology. 89(2). 163–169. 12 indexed citations

13.

Esterbauer, Harald, Gregor Hron, Cathrin Skrabs, et al.. (2008). Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. Leukemia & lymphoma. 49(2). 237–246. 5 indexed citations

14.

Vanura, Katrina, Trang Le, Harald Esterbauer, et al.. (2008). Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica. 93(12). 1912–1916. 20 indexed citations

15.

Wöhrer, Stefan, Marlene Troch, Jochen Zwerina, et al.. (2007). Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Annals of Oncology. 18(4). 647–651. 14 indexed citations

16.

Hauswirth, Alexander W., et al.. (2007). Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leukemia & lymphoma. 48(6). 1139–1149. 66 indexed citations

17.

Wöhrer, Stefan, Marlene Troch, Berthold Streubel, et al.. (2007). MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia. 21(8). 1812–1818. 77 indexed citations

18.

Hejna, Michael, Cathrin Skrabs, Johannes Drach, et al.. (2005). Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma. Oncology. 69(6). 499–502. 6 indexed citations

19.

Mitterbauer‐Hohendanner, Gerlinde, Christine Mannhalter, Karin Winkler, et al.. (2004). Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). Leukemia. 18(6). 1102–1107. 31 indexed citations

20.

Häuser, I, German Ott, Johannes Drach, et al.. (2003). Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia. 18(1). 146–155. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact